サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722974

放射線皮膚炎の市場規模、シェア、動向、予測：製品、流通チャネル、地域別、2025年～2033年

Radiodermatitis Market Size, Share, Trends and Forecast by Product, Distribution Channel, and Region, 2025-2033

出版日
発行
IMARC
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.73円
放射線皮膚炎の市場規模、シェア、動向、予測：製品、流通チャネル、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚炎の世界市場規模は2024年に5億1,478万米ドルとなりました。今後、IMARC Groupは、市場は2033年までに6億6,802万米ドルに達し、2025年から2033年にかけて2.94%のCAGRを示すと予測しています。現在、アジア太平洋地域が市場を独占しており、2024年の市場シェアは34％を超えています。放射線皮膚炎の市場シェアは、世界のがん患者数の増加、治療方法の進歩の高まり、非侵襲的で患者中心の治療に対する需要の高まりによって拡大しています。

放射線皮膚炎は、がんの治療に用いられる放射線療法によって引き起こされる皮膚症状を指します。一般に、乳房、肺、皮膚、頸部、頭部、肛門周囲など、皮膚が標的領域の一部である部位のがん患者において、がん治療中またはインターベンショナル・ラジオロジー後に副作用として発生します。放射線皮膚炎を治療するために一般的に使用されている製品には、局所抗生物質、コルチコステロイド、親水性クリーム、ハイドロゲルおよびハイドロコロイドドレッシング材、シリコーンコーティングドレッシング材、銀箔ドレッシング材、経口鎮痛剤、抗炎症剤などがあります。近年、放射線皮膚炎治療は、不快感を軽減し、痛みを最小限に抑え、患者の全体的な生活の質を向上させながら、継続的な治療の中断を防ぐことができるため、支持を集めています。

放射線皮膚炎の市場の動向：

がんの蔓延と治療オプションとしての放射線療法の採用増加は、市場成長を促進する主な要因です。これに加えて、世界の高齢人口の増加や放射線治療の副作用対策へのニーズの高まりが、放射線皮膚炎の治療への需要を増大させています。さらに、多くの政府機関や非政府機関が、利用可能な放射線皮膚炎の治療・管理製品に関する認識を広めるために積極的な取り組みを行っています。これは、ライフサイエンス分野で進行中の研究開発（R&D）活動への公的・民間投資の増加と相まって、市場成長の触媒となっています。さらに、大手企業は製品ポートフォリオを拡大し競争力を高めるため、革新的な製品の開発に注力しています。さらに、臨床試験件数の増加、有利な政府政策、消費者の支出能力の増加、ヘルスケアインフラの改善、ジェネリック医薬品の容易な入手などが、市場の見通しを明るいものにしています。

本レポートで扱う主な質問

  • 放射線皮膚炎の市場の規模は？
  • 放射線皮膚炎の市場の将来展望は？
  • 放射線皮膚炎の市場を牽引する主要因は何か？
  • 放射線皮膚炎の市場で最大のシェアを占める地域は？
  • 世界の放射線皮膚炎の市場における主要企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の放射線皮膚炎市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 外用
    • 主要セグメント
      • コルチコステロイド
      • 親水性クリーム
      • 抗生物質
      • その他
  • 経口
  • ドレッシング
    • 主要セグメント
      • ハイドロゲルおよびハイドロコロイドドレッシング
      • 刺傷防止フィルム
      • 蜂蜜を染み込ませたガーゼ
      • シリコンコーティングドレッシング
      • その他

第7章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • 3M Company
    • Bausch Health Companies Inc.
    • Bayer AG
    • BMG PHARMA S.p.A.
    • Charles River Laboratories International Inc.
    • ConvaTec Group plc
    • Helsinn Healthcare SA
    • ICON plc
    • Integra LifeSciences
    • Molnlycke Health Care AB
    • Stratpharma AG
図表

List of Figures

  • Figure 1: Global: Radiodermatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Radiodermatitis Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Radiodermatitis Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Radiodermatitis Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Radiodermatitis Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Radiodermatitis (Topical) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Radiodermatitis (Topical) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Radiodermatitis (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Radiodermatitis (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Radiodermatitis (Dressings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Radiodermatitis (Dressings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Radiodermatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Radiodermatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Radiodermatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Radiodermatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Radiodermatitis (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Radiodermatitis (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: North America: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: North America: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: United States: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: United States: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Canada: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Canada: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia-Pacific: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia-Pacific: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: China: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: China: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Japan: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Japan: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: India: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: India: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: South Korea: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: South Korea: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Australia: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Australia: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Indonesia: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Indonesia: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Others: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Others: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Europe: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Europe: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Germany: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Germany: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: France: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: France: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United Kingdom: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United Kingdom: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Italy: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Italy: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Spain: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Spain: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Russia: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Russia: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Latin America: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Latin America: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Brazil: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Brazil: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Mexico: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Mexico: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Middle East and Africa: Radiodermatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Middle East and Africa: Radiodermatitis Market: Breakup by Country (in %), 2024
  • Figure 67: Middle East and Africa: Radiodermatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Global: Radiodermatitis Industry: SWOT Analysis
  • Figure 69: Global: Radiodermatitis Industry: Value Chain Analysis
  • Figure 70: Global: Radiodermatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiodermatitis Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Radiodermatitis Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Radiodermatitis Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: Radiodermatitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Radiodermatitis Market: Competitive Structure
  • Table 6: Global: Radiodermatitis Market: Key Players
目次
Product Code: SR112025A5638

The global radiodermatitis market size was valued at USD 514.78 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 668.02 Million by 2033, exhibiting a CAGR of 2.94% from 2025-2033. Asia Pacific currently dominates the market, holding a market share of over 34% in 2024. The radiodermatitis market share is expanding, driven by the increasing numbers of cancer patients worldwide, heightened advancements in treatment modalities, and rising demand for the non-invasive, patient-centered treatments.

Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient's life.

Radiodermatitis Market Trends:

The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.

Key Market Segmentation:

Breakup by Product:

  • Topical
  • Corticosteroids
  • Hydrophilic Creams
  • Antibiotics
  • Others
  • Oral
  • Dressings
  • Hydrogel and Hydrocolloid Dressings
  • No Sting Barrier Film
  • Honey Impregnated Gauze
  • Silicone Coated Dressings
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Molnlycke Health Care AB and Stratpharma AG.

Key Questions Answered in This Report

  • 1.How big is the radiodermatitis market?
  • 2.What is the future outlook of radiodermatitis market?
  • 3.What are the key factors driving the radiodermatitis market?
  • 4.Which region accounts for the largest radiodermatitis market share?
  • 5.Which are the leading companies in the global radiodermatitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiodermatitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Topical
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Corticosteroids
      • 6.1.2.2 Hydrophilic Creams
      • 6.1.2.3 Antibiotics
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Oral
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Dressings
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Hydrogel and Hydrocolloid Dressings
      • 6.3.2.2 No Sting Barrier Film
      • 6.3.2.3 Honey Impregnated Gauze
      • 6.3.2.4 Silicone Coated Dressings
      • 6.3.2.5 Others
    • 6.3.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 3M Company
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Bausch Health Companies Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 BMG PHARMA S.p.A.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Charles River Laboratories International Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 ConvaTec Group plc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Helsinn Healthcare SA
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 ICON plc
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Integra LifeSciences
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Molnlycke Health Care AB
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 SWOT Analysis
    • 13.3.11 Stratpharma AG
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio